 | Up a level |
Journal Article
Janjigian, Yelena Y., Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan 
ORCID: 0000-0003-0808-6892, Yamaguchi, Kensei, Skoczylas, Tomasz ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Schenker, Michael ORCID: 0000-0003-2645-6391, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V., Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M., Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Ajani, Jaffer A.
(2021).
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet, 398 (10294).
S. 27 - 41.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X